Toshima Z Parris (Toshima Parris)

ResearcherID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 19

Top Venues

Scientific reports

Cell death discovery

International journal of molecular sciences

Cancer reports (Hoboken, N.J.)

University of Gothenburg

University of Gothenburg (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Gothenburg

Sweden

Researcher :: Department of Oncology

University of Gothenburg

Sweden

Postdoctoral researcher :: Dept. of Oncology

Sahlgrenska University Hospital

Sweden

Postdoctoral researcher :: Depts. of Oncology and Radiation Physics

University of Gothenburg

Sweden

Laboratory Assistant :: Department of Oncology

Nova Southeastern University

United States

Administrative Assistant of Licensure & Technical Services :: Doctoral Program for Educational Leaders

Nova Southeastern University

United States

Dissertation Secretary :: Doctoral Program for Educational Leaders

Education History

University of Gothenburg Jan 01 2008 - Jan 16 2014

Sweden

PHD :: Department of Oncology

University of Gothenburg

Sweden

BSC

Publications

Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers. Scientific reports 14 (1) (2024)
Peter Larsson, Daniella Pettersson, Maxim Olsson, Sithumini Sarathchandra, Alexandra Abramsson, Henrik Zetterberg, Ella Ittner, Eva Forssell-Aronsson, Anikó Kovács, Per Karsson, Khalil Helou, Toshima Z Parris
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Peter Larsson, Maria Cristina De Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties. Scientific reports 14 (1) (2024)
Charlotte Ytterbrink, Emman Shubbar, Toshima Z Parris, Britta Langen, Malin Druid, Emil Schüler, Sven-Erik Strand, Bo Åkerström, Magnus Gram, Khalil Helou, Eva Forssell-Aronsson
Effects of Recombinant α 1 -Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177 Lu-Octreotate. International journal of molecular sciences 25 (13) (2024)
Charlotte Ytterbrink, Emman Shubbar, Toshima Z Parris, Britta Langen, Malin Druid, Emil Schüler, Sven-Erik Strand, Bo Åkerström, Magnus Gram, Khalil Helou, Eva Forssell-Aronsson
Effects of Recombinant α 1 -Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177 Lu-Octreotate. International journal of molecular sciences 25 (13) (2024)
Peter Larsson, Maria Cristina De Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties. Scientific reports 14 (1) (2024)
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers. Scientific reports 14 (1) (2024)
Peter Larsson, Maria Cristina De Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties. Scientific reports 14 (1) (2024)
Charlotte Ytterbrink, Emman Shubbar, Toshima Z Parris, Britta Langen, Malin Druid, Emil Schüler, Sven-Erik Strand, Bo Åkerström, Magnus Gram, Khalil Helou, Eva Forssell-Aronsson
Effects of Recombinant α 1 -Microglobulin on Early Proteomic Response in Risk Organs after Exposure to 177 Lu-Octreotate. International journal of molecular sciences 25 (13) (2024)
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers. Scientific reports 14 (1) (2024)
Peter Larsson, Daniella Pettersson, Maxim Olsson, Sithumini Sarathchandra, Alexandra Abramsson, Henrik Zetterberg, Ella Ittner, Eva Forssell-Aronsson, Anikó Kovács, Per Karsson, Khalil Helou, Toshima Z Parris
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological cancers. Scientific reports 14 (1) (2024)
Peter Larsson, Daniella Pettersson, Maxim Olsson, Sithumini Sarathchandra, Alexandra Abramsson, Henrik Zetterberg, Ella Ittner, Eva Forssell-Aronsson, Anikó Kovács, Per Karsson, Khalil Helou, Toshima Z Parris
Repurposing proteasome inhibitors for improved treatment of triple-negative breast cancer. Cell death discovery 10 (1) (2024)
Peter Larsson, Maria Cristina De Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor properties. Scientific reports 14 (1) (2024)
Nina Oparina, Malin C Erlandsson, Anna Fäldt Beding, Toshima Z Parris, Khalil Helou, Per Karsson, Zakaria Einbeigi, Maria I Bokarewa
Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts. Cancers 13 (9) (2021)
Jenny Nyqvist, Anikó Kovács, Zakaria Einbeigi, Per Karlsson, Eva Forssell-Aronsson, Khalil Helou, Toshima Z Parris
Genetic alterations associated with multiple primary malignancies. Cancer medicine 10 (13) (2021)
Katarina Truvé, Toshima Z Parris, Dzeneta Vizlin-Hodzic, Susanne Salmela, Evelin Berger, Hans Ågren, Keiko Funa
Identification of candidate genetic variants and altered protein expression in neural stem and mature neural cells support altered microtubule function to be an essential component in bipolar disorder. Translational psychiatry 10 (1) (2020)
Toshima Z Parris, Dzeneta Vizlin-Hodzic, Susanne Salmela, Keiko Funa
Tumorigenic effects of TLX overexpression in HEK 293T cells. Cancer reports (Hoboken, N.J.) 2 (5) (2019)
Jana Biermann, Britta Langen, Szilárd Nemes, Erik Holmberg, Toshima Z Parris, Elisabeth Werner Rönnerman, Hanna Engqvist, Anikó Kovács, Khalil Helou, Per Karlsson
Radiation-induced genomic instability in breast carcinomas of the Swedish hemangioma cohort. Genes, chromosomes & cancer 58 (9) (2019)

Toshima Z Parris.css-eqlu8i{font-size:small;padding-left:4px;} (Toshima Parris)

Publication Activity (10 Years)

Top Topics

Top Venues

Toshima Z Parris (Toshima Parris)